Table 1.

Clinical trials of mepolizumab in asthma.

Study	Disease severity	Dosage/delivery	Outcome summary
[Menzies-Gow et al. 2003]	Mild asthmatics	750 mg iv every 4 weeks for 3 months	↓ Eosinophils within bronchial mucosa
[Flood-Page et al. 2003]	Mild asthmatics	750 mg iv every 4 weeks for 3 months	↓ Blood eosinophils ↓ Airway eosinophils by 50% No effect on PEF, FEV1 and bronchial hyperresponsiveness
[Flood-Page et al. 2007]	Moderate asthmatics	250 or 750 mg iv every 4 weeks for 3 months	↓ Blood and sputum eosinophils No effect on PEF, FEV1 and AQLQ
[Haldar et al. 2009]	Severe eosinophilic asthmatics	750 mg iv every 4 weeks for 1 year	↓ Blood eosinophils ↓ Exacerbations ↑ AQLQ No effect on FEV1
[Nair et al. 2009]	Prednisone-dependent eosinophilic asthmatics	750 mg iv every 4 weeks for 5 months	↓ Blood and sputum eosinophils ↓ Exacerbations Prednisone-sparing effect
[Pavord et al. 2012]	Severe eosinophilic asthmatics	1 of 3 doses (750, 250 or 75 mg) iv every 4 weeks for 13 months	↓ Blood and sputum Eosinophils ↓ Exacerbations No effect on FEV1 and AQLQ
[Ortega et al. 2014b]	Severe eosinophilic asthmatics MENSA STUDY	100 mg sc every 4 weeks for 8 months	↓ Blood eosinophilia ↓ Exacerbations ↑ FEV1 ↑ ACQ-5 score
[Bel et al. 2014]	Severe eosinophilic asthmatics SIRIUS STUDY	100 mg sc every 4 weeks for 6 months	↓ Blood eosinophils ↓ Exacerbations Glucocorticoid sparing-effect ↑ ACQ-5 score
[Haldar et al. 2014]	Severe eosinophilic asthmatics	750 mg iv every 4 weeks Outcome after cessation	Rapid increase in blood and sputum eosinophils followed by increased of asthma symptoms and exacerbations

ACQ-5, Asthma Control Questionnaire-5; AQLQ, Asthma Quality of Life Questionnaire; FEV₁, forced expiratory volume in one second; iv, intravenously; PEF, peak expiratory flow; sc, subcutaneously.